Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Mainwaring

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)Hans-Joachim Schmoll, David Cunningham, Alberto Sobrero, et al.
The Lancet. Oncology|July 21, 2009
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trialMartin E Gore, Cezary Szczylik, Camillo Porta, et al.
ACS Sensors|June 5, 2024
A Mesoporous Gold Sensor Unveils Phospho PD-L1 in Extracellular Vesicles as a Proxy for PD-L1 Expression in Lung Cancer TissueKarthik B Shanmugasundaram, Emtiaz Ahmed, Xinzhe Miao, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 7, 2015
A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancerRebecca L Prue, Frank Vari, Kristen J Radford, et al.
The Lancet. Oncology|September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Howard I Scher, Arturo Molina, et al.
The New England Journal of Medicine|August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapyHoward I Scher, Karim Fizazi, Fred Saad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2016
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1Matthew Smith, Johann De Bono, Cora Sternberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast CancerPeter Schmid, Sarah E Pinder, Duncan Wheatley, et al.
European Urology|May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
The New England Journal of Medicine|June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapyTomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)Hans-Joachim Schmoll, David Cunningham, Alberto Sobrero, et al.
The Lancet. Oncology|July 21, 2009
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trialMartin E Gore, Cezary Szczylik, Camillo Porta, et al.
ACS Sensors|June 5, 2024
A Mesoporous Gold Sensor Unveils Phospho PD-L1 in Extracellular Vesicles as a Proxy for PD-L1 Expression in Lung Cancer TissueKarthik B Shanmugasundaram, Emtiaz Ahmed, Xinzhe Miao, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 7, 2015
A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancerRebecca L Prue, Frank Vari, Kristen J Radford, et al.
The Lancet. Oncology|September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Howard I Scher, Arturo Molina, et al.
The New England Journal of Medicine|August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapyHoward I Scher, Karim Fizazi, Fred Saad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2016
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1Matthew Smith, Johann De Bono, Cora Sternberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast CancerPeter Schmid, Sarah E Pinder, Duncan Wheatley, et al.
European Urology|May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
The New England Journal of Medicine|June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapyTomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
Pageof 4